Guidelines: onkopedia - what´s new? Locally advanced rectal cancer.

IF 2 4区 医学 Q3 ONCOLOGY Oncology Research and Treatment Pub Date : 2024-09-17 DOI:10.1159/000541376
Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann
{"title":"Guidelines: onkopedia - what´s new? Locally advanced rectal cancer.","authors":"Ralf-Dieter Hofheinz,Dirk Arnold,Markus Borner,Wolfgang Eisterer,Gunnar Folprecht,Michael Ghadimi,Ullrich Graeven,Birgit Grünberger,Holger Hebart,Susanna Hegewisch-Becker,Volker Heinemann,Ron Pritzkuleit,Claus Rödel,Holger Rumpold,Tanja Trarbach,,Bernhard Wörmann","doi":"10.1159/000541376","DOIUrl":null,"url":null,"abstract":"This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian and Swiss onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy (TNT) for rectal cancers with high risk features, (ii) treatment with neoadjuvant chemotherapy for patient with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high /dMMR rectal cancer as well as (iv) intended organ preservation as a treatment goal. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options and risks of individual treatment approaches.","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"1 1","pages":"1-9"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541376","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian and Swiss onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy (TNT) for rectal cancers with high risk features, (ii) treatment with neoadjuvant chemotherapy for patient with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high /dMMR rectal cancer as well as (iv) intended organ preservation as a treatment goal. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options and risks of individual treatment approaches.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
指南:百科全书 - 新内容?局部晚期直肠癌。
本文简要总结了最近出版的德国、奥地利和瑞士关于局部晚期直肠癌治疗指南中与临床相关的新内容。主要内容包括:(i) 对具有高风险特征的直肠癌采用全新药辅助治疗 (TNT);(ii) 对局部复发风险较低的患者采用新药辅助化疗;(iii) 对 MSI 高/dMMR 直肠癌患者采用多司马单抗进行免疫治疗;(iv) 将保留器官作为治疗目标。由于存在多种循证治疗方案,因此需要多学科团队进行深入讨论,并向患者提供有关治疗目标、方案和各种治疗方法风险的专门信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.20
自引率
0.00%
发文量
84
期刊介绍: With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
期刊最新文献
Survivorship in CAR T-cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse Mortality. Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany - Final results of the phase 2 multicohort INGE-B trial. ONKOPEDIA Guideline Updates "in a Nutshell" for the Readers of Oncology Research and Treatment. Sex-disaggregated analysis of central venous catheter-related bloodstream infections in patients with cancer. Standardizing Nutritional Care for Cancer Patients: Implementation and Evaluation of a Malnutrition Risk Screening.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1